MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
MannKind Corporation (MNKD) has scheduled its Q1 2025 financial results announcement for May 8, 2025, before market open. The company will host a webcast at 9:00 a.m. Eastern Time featuring CEO Michael Castagna and CFO Chris Prentiss to discuss the quarterly results and provide a business update. The webcast will be available through MannKind's investor relations website, with a replay accessible for approximately 90 days following the call.
MannKind Corporation (MNKD) ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per il 8 maggio 2025, prima dell'apertura dei mercati. La società terrà una webcast alle 9:00 ora della costa orientale con la partecipazione del CEO Michael Castagna e del CFO Chris Prentiss, che discuteranno i risultati trimestrali e forniranno un aggiornamento sull'attività aziendale. La webcast sarà disponibile sul sito web delle relazioni con gli investitori di MannKind, con una replica accessibile per circa 90 giorni dopo la chiamata.
MannKind Corporation (MNKD) ha programado el anuncio de los resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025, antes de la apertura del mercado. La compañía realizará una transmisión en vivo a las 9:00 a.m. hora del Este con el CEO Michael Castagna y el CFO Chris Prentiss, quienes discutirán los resultados trimestrales y ofrecerán una actualización del negocio. La transmisión estará disponible a través del sitio web de relaciones con inversionistas de MannKind, con una repetición accesible durante aproximadamente 90 días después de la llamada.
MannKind Corporation (MNKD)는 2025년 1분기 재무 실적 발표를 2025년 5월 8일 시장 개장 전으로 예정했습니다. 회사는 CEO 마이클 카스타냐와 CFO 크리스 프렌티스가 분기 실적을 논의하고 사업 업데이트를 제공하는 웹캐스트를 동부 표준시 오전 9시에 진행할 예정입니다. 웹캐스트는 MannKind의 투자자 관계 웹사이트를 통해 제공되며, 통화 후 약 90일 동안 다시보기 이용이 가능합니다.
MannKind Corporation (MNKD) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 8 mai 2025, avant l'ouverture des marchés. La société organisera un webinaire à 9h00 heure de l'Est avec le PDG Michael Castagna et le CFO Chris Prentiss pour discuter des résultats trimestriels et fournir une mise à jour commerciale. Le webinaire sera accessible via le site des relations investisseurs de MannKind, avec un replay disponible pendant environ 90 jours après l'appel.
MannKind Corporation (MNKD) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 vor Börsenbeginn geplant. Das Unternehmen wird um 9:00 Uhr Eastern Time ein Webcast veranstalten, bei dem CEO Michael Castagna und CFO Chris Prentiss die Quartalsergebnisse besprechen und ein Geschäftsupdate geben. Der Webcast wird über die Investor-Relations-Website von MannKind verfügbar sein, mit einer Wiedergabe, die etwa 90 Tage nach dem Anruf zugänglich ist.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025.
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind: Investor Relations Ana Kapor (818) 661-5000 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com
FAQ
When will MannKind (MNKD) release its Q1 2025 earnings?
What time is MannKind's Q1 2025 earnings call?
Who will participate in MannKind's Q1 2025 earnings call?
How can I access MannKind's Q1 2025 earnings webcast?
